Wall Street analysts expect TearLab Corporation (NASDAQ:TEAR) to post earnings of ($0.70) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for TearLab Corporation’s earnings, with the lowest EPS estimate coming in at ($0.73) and the highest estimate coming in at ($0.64). TearLab Corporation also posted earnings of ($0.70) per share in the same quarter last year. The company is scheduled to announce its next quarterly earnings results on Monday, November 6th.

According to Zacks, analysts expect that TearLab Corporation will report full year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($2.76) to ($2.64). For the next financial year, analysts expect that the business will report earnings of ($1.59) per share, with EPS estimates ranging from ($2.04) to ($1.36). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow TearLab Corporation.

TearLab Corporation (NASDAQ:TEAR) last released its quarterly earnings results on Monday, August 14th. The medical research company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. The firm had revenue of $7 million for the quarter, compared to analysts’ expectations of $6.86 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis.

TEAR has been the subject of a number of analyst reports. Zacks Investment Research raised shares of TearLab Corporation from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Friday. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of TearLab Corporation in a research note on Tuesday. Finally, Rodman & Renshaw cut their target price on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, May 16th. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $4.95.

ILLEGAL ACTIVITY NOTICE: “-$0.70 Earnings Per Share Expected for TearLab Corporation (TEAR) This Quarter” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/19/0-70-earnings-per-share-expected-for-tearlab-corporation-tear-this-quarter.html.

Shares of TearLab Corporation (NASDAQ TEAR) traded down 1.84% during mid-day trading on Friday, hitting $1.60. The stock had a trading volume of 135,124 shares. The stock’s market cap is $9.19 million. The company’s 50 day moving average price is $2.10 and its 200 day moving average price is $2.81. TearLab Corporation has a 12-month low of $1.53 and a 12-month high of $8.20.

About TearLab Corporation

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Get a free copy of the Zacks research report on TearLab Corporation (TEAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.